摘要:目的: 比較咪達(dá)普利與培哚普利對原發(fā)性高血壓患者的的降壓效果和不良反應(yīng)。 方法 :將入選的60例1～2級高血壓病患者,隨機(jī)分為2組,咪達(dá)普利組,每日晨起口服咪達(dá)普利(5～10 mg,1次/d),培哚普利組,每日晨起口服培哚普利(4～8 mg,1次/d)。治療4周,觀察2組治療前、后的血壓,記錄不良反應(yīng)。 結(jié)果 :經(jīng)治療后咪達(dá)普利與培哚普利組血壓均明顯下降(Plt;0.05),組間差異無統(tǒng)計學(xué)意義(P＞0.05);總不良反應(yīng)發(fā)生率咪達(dá)普利組16.8%,培哚普利組20%,而咪達(dá)普利組的咳嗽發(fā)生率為6.8%,培哚普利組為16.8%。 結(jié)論 :咪達(dá)普利和培哚普利均能有效降壓,二者降壓效果相似,但咪達(dá)普利的咳嗽發(fā)生率較低。Abstract: Objective: To compare the antihypertensive efficacy and safety of imidapril versus peridopril in patients with essential hypertension. Methods : Selected 60 patients with mild to moderate essential hypertension, in which divided two groups by random.They were administered imidapril 5～10 mg once daily or and peridopril 4～8 mg once daily for 4 weeks. During the curative period of 4 weeks, the antihypertensive efficacy and adverse reaction were observed. Results :The blood pressure drecreased prominently in both groups after four weeks treament(Plt;0.05), but there was no significant difference in antihypertensive efficacy between the two groups(P＞0.05). The occurrence of the total adverse reaction in imidapril and peridopril groups was 16.8% and 20%, respectively, while the occurrence of the cough in two groups was 6.8% and 16.8%, respectively. Conclusion :Both imidapril and peridopril exert favourable and similar hepotensive effect, however the cough occurrence of imidapril is lower than that of peridopril.
目的總結(jié)體液中環(huán)狀 RNA 在疾病診斷中作用的研究進(jìn)展。方法通過閱讀國內(nèi)外關(guān)于體液環(huán)狀 RNA 在疾病診斷方面的相關(guān)文獻(xiàn)，歸納總結(jié)其研究進(jìn)展。結(jié)果環(huán)狀 RNA 作為內(nèi)源性環(huán)狀 RNA 分子，因其結(jié)構(gòu)穩(wěn)定、序列保守、功能多樣、組織細(xì)胞特異性等特點，被發(fā)現(xiàn)與多種疾病相關(guān)。近來研究發(fā)現(xiàn)，環(huán)狀 RNA 可被分泌至外周血、唾液、尿液、胃液、精漿等體液中，且可穩(wěn)定存在，并與心血管疾病、神經(jīng)系統(tǒng)疾病、自身免疫性疾病、各類惡性腫瘤、代謝性疾病等多種疾病相關(guān)，具有作為疾病非侵入性檢測生物標(biāo)志物之重要潛能。結(jié)論目前研究發(fā)現(xiàn)，體液環(huán)狀 RNA 與多種臨床疾病的診斷相關(guān)，因此對體液環(huán)狀 RNA 與疾病診斷關(guān)系的深入研究有助于開發(fā)臨床疾病非侵入性診斷標(biāo)志物，對于疾病的非侵入性診斷具有重要意義。